Latest news with #TNF
Business Wire
a day ago
- Business
- Business Wire
Candid Therapeutics Advances Portfolio of Novel T-Cell Engagers into Five Autoimmune Diseases for Clinical Evaluation
SAN DIEGO--(BUSINESS WIRE)--Candid Therapeutics, Inc. ('Candid'), a clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs), today announced key operational and clinical milestones for its two lead clinical stage programs, cizutamig (BCMA TCE) and CND261 (CD20 TCE). Candid launched in the second half of 2024 with $370 million in financing and two in-licensed TCEs that had completed full Phase 1 dose escalation studies in oncology patients. Emerging clinical data with TCEs have solidified our confidence that TCEs can become the most compelling modality across a range of diseases. Share 'We founded Candid on the conviction that T-cell engagers would become the largest therapeutic class in autoimmune diseases, surpassing the commercial success of TNF inhibitors such as Humira,' said Dr. Ken Song, Chairman, President, and Chief Executive Officer of Candid. 'We are hyperfocused on execution to generate clinical data. Over the past few quarters, we have prioritized disease indications and built a foundation of key CMC and clinical operational activities to set a new benchmark for innovation, scale, and speed. Emerging clinical data with TCEs have solidified our confidence that TCEs can become the most compelling modality across a range of diseases.' Key Highlights Reinforcing Candid's Leadership Position: First patients dosed with cizutamig and CND261: Patients with refractory rheumatoid arthritis and systemic sclerosis have been dosed at therapeutically active doses. Both TCEs have been well tolerated and patients have shown early signs of promising clinical response and disease improvement. Industry-leading clinical study pipeline in motion: Clinical studies are now in progress for IgA Nephropathy, Myasthenia Gravis, Rheumatoid Arthritis, Systemic Lupus Erythematosus and Systemic Sclerosis. Additional clinical studies in high-value disease indications slated to launch in the 2H 2025. Studies are designed to evaluate safety, pharmacokinetics, pharmacodynamic effects, and early signs of efficacy in patients with immunology and inflammatory diseases. CMC activities completed to enable global clinical trials: Candid has invested significant resources to build an integrated Chemistry, Manufacturing, and Controls (CMC) infrastructure to support global development with the completion of several new drug product manufacturing runs. Subcutaneous dosing formulations for both cizutamig and CND261 have been established. Strategic establishment of China operations: To support clinical execution across multiple geographies, Candid has established a fully staffed legal entity in China. The China based team includes professionals with deep expertise in regulatory, clinical development, and clinical operations. With unmatched executional momentum and differentiated programs, Candid Therapeutics is defining a new future in immunology through its commitment to TCEs in autoimmune diseases. Additional trial initiations and clinical data disclosures are anticipated in the coming quarters. About Candid Therapeutics Candid Therapeutics is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune and inflammatory diseases through novel T-cell engager (TCE) platforms. Candid is advancing two lead B-cell depleting TCE antibody drug candidates, with a goal to broadly explore the potential of TCEs across multiple autoimmune diseases by targeting different B-cell protein targets, as well as evaluating different depths of B-cell depletion. Established in 2024 and headquartered in San Diego, CA, Candid is led by a team of entrepreneurial executives who have a track record of advancing programs into and through development and is supported by a distinguished syndicate of premier life science investors. About Cizutamig Cizutamig is a bispecific antibody designed to simultaneously bind B-cell maturation antigen (BCMA) on B-cells and CD3 on T-cells, enabling T-cell–mediated cytotoxicity against BCMA-expressing B-cells. Originally developed and clinically evaluated in multiple myeloma, cizutamig has demonstrated patient experience in oncology settings and is now being investigated in autoimmune diseases where pathogenic B-cells play a critical role in disease progression. Cizutamig has the potential to deliver deep and selective B-cell depletion through its dual-targeting mechanism, offering a novel approach for treating a broad spectrum of immune-mediated disorders. About CND261 CND261 is a bispecific antibody designed to target CD20 on B-cells and CD3 on T-cells, enabling T-cell mediated cytotoxicity against CD20-expressing B-cells. Engineered with low CD3 affinity, CND261 is optimized to reduce the risk of excessive T-cell activation while maintaining potent and selective B-cell depletion. The molecule has demonstrated patient experience in B-cell malignancies and is now being investigated in autoimmune diseases where pathogenic B-cells contribute to disease progression. CND261 represents a promising therapeutic candidate for immune-mediated disorders with the potential for improved safety and efficacy through its targeted mechanism of action.
Medscape
11-06-2025
- Health
- Medscape
Cancer Risk High in Ulcerative Colitis, Varies by Age
Compared with the general population, patients with ulcerative colitis (UC) had an additional risk of developing cancer, with about two to three more cases per 1000 person-years, regardless of immunomodulatory treatment status. Variations in the incidence of cancer were particularly noted with age. METHODOLOGY: Researchers conducted a nationwide cohort study using Swedish health registers with prospectively captured data on patients with incident or prevalent UC from routine medical practice from January 2007 to December 2021. They analysed 63,925 patients with UC who were matched with 593,072 comparators from the general population without inflammatory bowel disease. Exposure to drugs for UC, including thiopurine, TNF inhibitors (infliximab, adalimumab, or golimumab), combined treatment with thiopurine and TNF inhibitors, vedolizumab, ustekinumab, and tofacitinib, was assessed. The absolute and excess occurrence of cancer in patients with UC, regardless of their exposure to specific UC medications, was compared with the incidence of cancer in the general population at 1 year after drug exposure. Incident cancers, including cancers associated with UC, thiopurine, or TNF inhibitors and other common cancers, were identified using codes in treatment-naive patients and those exposed to drugs. TAKEAWAY: Incidence rate differences for any cancer compared with the general population were 2.66 cases per 1000 person-years in the treatment-naive cohort, 3.38 in the thiopurine-treated cohort, 2.69 in the TNF inhibitor-treated cohort, 2.42 in the thiopurine plus TNF inhibitor-treated cohort, and 2.88 in the vedolizumab-treated cohort. The risk for any cancer was higher in the treatment-naive cohort (hazard ratio [HR], 1.12; 95% CI, 1.09-1.16) and in those treated with thiopurine (HR, 1.48; 95% CI, 1.37-1.61), TNF inhibitor (HR, 1.41; 95% CI, 1.24-1.62), thiopurine plus TNF inhibitor (HR, 1.44; 95% CI, 1.19-1.75), and vedolizumab (HR, 1.27; 95% CI, 0.90-1.79) than in the general population. The incidence rate differences for any cancer were more pronounced in middle-aged (40 to < 60 years) and older (≥ 60 years) patients, showing 1.76 to 1.57 cases per 1000 person-years in the naive cohort and 3.45 to 9.69 cases per 1000 person-years in the thiopurine-treated cohort. However, the risks were increased in younger patients (18 to < 40 years) but rarely in older patients. The highest risks were observed for hepatobiliary cancer across treatment groups (naive, thiopurine, TNF inhibitor, and thiopurine plus TNF inhibitor), followed by colorectal cancer and lymphoma that were noted in all these groups except the naive group. IN PRACTICE: "Screening of patients with IBD [inflammatory bowel disease] for other forms of cancer, such as hepatobiliary cancer and basal cell skin carcinoma, has been suggested," the authors wrote. SOURCE: This study was led by Åsa H. Everhov, Karolinska Institutet, Stockholm, Sweden. It was published online on June 02, 2025, in the Journal of Crohn's and Colitis . LIMITATIONS: The follow-up time for assessing cancer was shorter and varied between treatment groups. The study design was not intended to compare treatment groups directly owing to pronounced differences in age and disease severity between different treatment groups. A once exposed-always exposed approach was used, and the actual exposure time was not considered. DISCLOSURES: This study was supported by grants from the Swedish Research Council, Swedish Cancer Society, and Regional Agreement on Medical Training and Clinical Research between Stockholm County Council and Karolinska Institutet. Some authors reported receiving financial support or research grants; collaborating on research; and serving as principal investigators, speakers, and/or advisory board members for various pharmaceutical companies.
USA Today
19-05-2025
- Sport
- USA Today
Matt LaFleur: 'Interesting' that NFL scheduled Packers a Week 5 bye after Week 2 TNF game
Matt LaFleur: 'Interesting' that NFL scheduled Packers a Week 5 bye after Week 2 TNF game Green Bay Packers coach Matt LaFleur doesn't sound particularly pleased with the way the NFL scheduled the team's bye during the 2025 regular season. In recent interviews with both Larry McCarren of and Chris Simms of NBC Sports, LaFleur mentioned the peculiar decision to give the Packers a bye week in Week 5 after scheduling a Week 2 game on Thursday night. The Packers have the earliest possible bye week and will also play the league's first "Thursday Night Football" game in Week 2. "It is interesting having the short week in Week 2 after we play Washington followed up by a Week 5 bye, but we'll adjust to it," LaFleur told McCarren. "It's interesting, you have a real quick turnaround in Week 2 getting a Thursday night game against a really talented Washington Commanders team, and then we have an early bye, which is kind of weird after that Thursday night game, but it is what it is," LaFleur told Simms. Not only is the Packers' bye week early, but having the short week in Week 2 creates a disjointed start to Green Bay's season and an odd mix of early rest for LaFleur's team. Teams playing on "Thursday Night Football" often talk about having a "mini-bye" the next week considering the rest and prep advantage. The guess here is LaFleur doesn't love the Week 5 bye week mostly because his team will get a "mini-bye" right away to start the season. The Packers are scheduled to host the Detroit Lions on Sunday, Sept. 7 and then welcome the Washington Commanders to Lambeau Field for "TNF" on Thursday, Sept. 11 -- a two-game stretch against NFC playoff opponents from 2024 in a five-day period. The Packers won't play again until Sept. 21, providing a 10-game layoff between Week 2 and Week 3. With a Week 5 bye, the Packers will play four games to start the season (with a mini-bye mixed in) and then have a grueling 13-game stretch to end the season, including four of six away from home to end the year. When asked by McCarren what else he cares about the schedule, LaFleur pointed to short, irregular weeks. Not only do the Packers play twice on Thursday and at least once on Saturday, the Packers actually lead the NFL in short weeks before road games with three and have four games with a rest/prep disadvantage. "Bottom line, you have to adjust, you have to be ready to play, wherever they tell you to play, when they tell you to play, and just be ready to play your best," LaFleur said.
Yahoo
15-05-2025
- Business
- Yahoo
Enbrel (Etanercept) Market Research Report 2025: Epidemiology, Pipeline Analysis, Insights & Forecasts 2019-2024, 2024-2029F, 2034F
Dublin, May 15, 2025 (GLOBE NEWSWIRE) -- The "Enbrel (Etanercept) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to Enbrel (Etanercept) market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market. Enbrel (etanercept) is a biologic medication that treats various autoimmune conditions by inhibiting the activity of tumor necrosis factor (TNF), a protein involved in inflammation. It is a synthetic version of a naturally occurring protein in the body, designed to bind to TNF and block its interaction with its receptors, reducing inflammation. Enbrel is usually administered through subcutaneous injection, either by a healthcare professional or by patients themselves at home. Major players operating in the enbrel (etanercept) market are Amgen Inc; Pfizer Inc. North America was the largest region in the enbrel (etanercept) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in enbrel (etanercept) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the enbrel (etanercept) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, primary types of enbrel (etanercept) include brand drugs and biosimilars. It is used to treat autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis by blocking TNF. Enbrel is available in both liquid solution and powder for injection growth observed during the historic period can be attributed to the approval of multiple indications, strong adoption by physicians, the introduction of patient-friendly injection devices, a growing healthcare focus on cost-effective treatments for chronic diseases, extensive clinical trials, and positive growth during the forecast period can be driven by the aging global population, the increasing prevalence of autoimmune diseases, rising preference for biologics, the introduction of biosimilars, and increased government funding and insurance coverage. Key trends during this period include its use in pediatric populations, a rise in home-based treatments, integration of digital health, combination therapy approaches, and advancements in genomics and biomarker surging prevalence of autoimmune conditions is expected to significantly propel the growth of the enbrel (etanercept) market. Autoimmune conditions, where the immune system mistakenly attacks the body's healthy tissues, are increasing due to factors such as genetic susceptibility, environmental triggers, and improved diagnosis and awareness. Enbrel, which inhibits tumor necrosis factor-alpha (TNF-a), is highly effective in treating autoimmune disorders such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. By blocking TNF-a, Enbrel helps reduce inflammation, alleviate symptoms, and slow disease progression. For instance, in June 2024, the Australian Institute of Health and Welfare reported that 514,000 Australians were living with rheumatoid arthritis in 2022. The increasing prevalence of such conditions will continue to drive demand for enbrel.A key trend in the enbrel (etanercept) market is the development of innovative TNF inhibitors to manage autoimmune diseases. TNF inhibitors block the TNF protein, which is responsible for inflammation and immune responses, thereby helping to reduce symptoms like joint swelling and pain. In October 2023, Amgen Inc. received U.S. Food and Drug Administration (FDA) approval for Enbrel to manage juvenile psoriatic arthritis (JPsA) in children aged two and older. This approval marks a significant advancement in the use of Enbrel for younger Topics Covered: 1. Executive Summary2. Enbrel (Etanercept) Market Characteristics3. Enbrel (Etanercept) Market Biologic Drug Characteristics3.1. Molecule Type3.2. Route of Administration (ROA)3.3. Mechanism of Action (MOA)3.4. Safety and Efficacy4. Enbrel (Etanercept) Market Trends and Strategies5. Enbrel (Etanercept) Market - Macro Economic Scenario Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market6. Global Enbrel (Etanercept) Growth Analysis and Strategic Analysis Framework6.1. Global Enbrel (Etanercept) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)6.2. Analysis of End Use Industries6.3. Global Enbrel (Etanercept) Market Growth Rate Analysis6.4. Global Enbrel (Etanercept) Historic Market Size and Growth, 2019-2024, Value ($ Billion)6.5. Global Enbrel (Etanercept) Forecast Market Size and Growth, 2024-2029, 2034F, Value ($ Billion)6.6. Global Enbrel (Etanercept) Total Addressable Market (TAM)7. Global Enbrel (Etanercept) Market Pricing Analysis & Forecasts8. Enbrel (Etanercept) Market Segmentation8.1. Global Enbrel (Etanercept) Market, Segmentation by Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Brands Drugs Biosimilar Drugs 8.2. Global Enbrel (Etanercept) Market, Segmentation by Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Liquid Solution Powder For Injections 8.3. Global Enbrel (Etanercept) Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Rheumatoid Arthritis Psoriatic Arthritis Ankylosing Spondylitis Juvenile Idiopathic Arthritis 9. Global Enbrel (Etanercept) Market Epidemiology of Clinical Indications9.1. Drug Side Effects9.2. Incidence and Prevalence of Clinical Indications10. Enbrel (Etanercept) Market Regional and Country Analysis10.1. Global Enbrel (Etanercept) Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion10.2. Global Enbrel (Etanercept) Market, Split by Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
USA Today
15-05-2025
- Sport
- USA Today
Breaking down most interesting matchups of all 18 weeks of the 2025 NFL schedule
Breaking down most interesting matchups of all 18 weeks of the 2025 NFL schedule Show Caption Hide Caption Five NFL games we can't wait to watch in the 2025 season The NFL schedule for the 2025-2026 season has been released. Here are a few games on our must-watch list. The NFL released its full, 272-game schedule for 2025 on Wednesday, officially marking the point many football fans start looking ahead to the upcoming season. Naturally, football junkies immediately began poring over the schedule to find its most exciting matchups. Often, those matchups are in primetime and feature matchups between some of the top projected teams in the league. However, there are also a handful of intriguing revenge games and homecoming that should be on the radar of NFL fans ahead of the 2025 season. What are the most interesting matchups of the 2025 campaign? Below is a look at one matchup on which to keep an eye each week. NFL schedule 2025: Most interesting matchups by week Week 1 If Aaron Rodgers signs with the Steelers, this could end up being a double revenge game. Rodgers, who has been tied to Pittsburgh throughout the offseason, would likely relish a chance to hand Aaron Glenn a defeat, as the veteran quarterback wasn't happy with how the Jets handled his release during the offseason. Meanwhile, Justin Fields started the first six games of last season for the Steelers, leading them to a 4-2 record before being benched in favor of Russell Wilson. He will have a chance to show Mike Tomlin and Co. what they missed by letting him walk in free agency. Week 2 Philadelphia Eagles at Kansas City Chiefs Ben Johnson's return to Detroit comes in a close second in a loaded Week 2 slate, but it's hard to overlook an early-season Super Bowl rematch. The Chiefs will be seeking vengeance after being blown out by the Eagles 40-22 in Super Bowl 59. It will be a great test for Kansas City's new-look offensive line and will also be a litmus test for the Eagles, who have replaced a handful of key starters on their defense, notably defensive linemen Milton Williams and Josh Sweat. Week 3 Miami Dolphins at Buffalo Bills The Dolphins and Bills met on "Thursday Night Football" in Week 2 last season. In that contest, Tua Tagovailoa suffered a concussion that knocked him out four weeks and helped cause Miami to get off to a slow start from which it couldn't recover. Miami will be looking to keep Tagovailoa healthy in its first of two "TNF" games while also looking to challenge the Bills early in the AFC East race. Week 4 Baltimore Ravens at Kansas City Chiefs Many believed Lamar Jackson and the Ravens might face the Chiefs in the postseason. Instead, the Bills knocked the Ravens out in the divisional round, robbing Baltimore of a chance to avenge its 27-20 regular-season loss to the Chiefs. The Ravens will get an early chance to see Patrick Mahomes and the Chiefs again. The Mahomes vs. Jackson battle will be one of the best quarterback matchups of the first four weeks of the NFL season, and both playmakers should bring their A-game to what figures to be an early battle for control of the AFC. Week 5 The Lions and Bengals sported two of the NFL's best offenses last season. Detroit averaged a league-high 33.1 points while ranking third in offensive EPA while the Bengals ranked seventh in points per game (27.8) and seventh in offensive EPA. Both offenses are returning a majority of their starters in 2025, so this figures to be an exciting shootout. It will also be a good test of the Lions' offensive ceiling after losing offensive coordinator Ben Johnson, who took the Bears coaching job during the NFL offseason. Week 6 Last time the Bears and Commanders met, Jayden Daniels completed an improbable Hail Mary to give Washington a win and send Chicago into a losing streak. The Bears lost 10 straight games following the Hail Mary and fired coach Matt Eberflus as it sputtered to a 5-12 finish. Suffice to say that game left a sour taste in Chicago's mouth. Caleb Williams will look to even up the series between the No. 1 and No. 2 picks in the 2024 NFL Draft while cornerback Tyrique Stevenson will look to atone for his lack of attention to detail during the Hail Mary throw. Week 7 New England Patriots at Tennessee Titans Mike Vrabel is back in the NFL coaching ranks after taking the Patriots' job following the dismissal of Jerod Mayo. He will return to Tennessee as he looks to prove the Titans made a mistake in firing him after the 2023 NFL season. Vrabel already has a slight edge on the Titans after they sputtered to a league-worst 3-14 record in Brian Callahan's first season with the team. Beating Tennessee with a rebuilding New England squad would provide another feather in the cap of the 2021 NFL Coach of the Year. Week 8 Green Bay Packers at Pittsburgh Steelers Aaron Rodgers has never played against the Packers after spending the first 18 seasons of his career in Green Bay. Could that change in Week 8? Again, Rodgers hasn't yet signed in Pittsburgh, but if he does, many fans will be eagerly watching to see if the 41-year-old can become the fifth quarterback in NFL history to beat all 32 teams. Tom Brady, Peyton Manning, Brett Favre and Drew Brees are the others. Week 9 Kansas City Chiefs at Buffalo Bills Five of the last six Bills vs. Chiefs games have been decided by one score. That has included three postseason matchups all won by Kansas City. Buffalo has typically performed well against its rival and has earned three consecutive regular-season wins over Kansas City. If the Bills can continue doing that, it may give them a path to the AFC's No. 1 seed. That makes this a rare midseason matchup that could prove crucial to the AFC playoff picture. Week 10 Detroit Lions at Washington Commanders The Lions' season ended at the hands of the Commanders in the divisional round of the NFC playoffs. Washington crushed Detroit 45-31 in a game during which Jared Goff threw three interceptions and the Lions defense couldn't stop Jayden Daniels. Dan Campbell's squad will be looking to avenge that loss, which brought to an early end one of the greatest seasons in Detroit's franchise history. With a healthier, Aidan Hutchinson-led defense, the Lions could have a better chance to compete with the NFC runners-up. Week 11 Detroit Lions at Philadelphia Eagles Here's our chance to see what many believed the NFC championship game would be last season. If the Lions can beat the Commanders and Eagles in back-to-back weeks, it will lead Detroit fans to wonder what may have happened if the team's defense was able to stay healthier in 2024. This matchup could also help to determine who has the inside track for the NFC's No. 1 seed in 2025, so this game will be an important one. Week 12 Tampa Bay Buccaneers at Los Angeles Rams The Buccaneers and Rams have both made the playoffs in back-to-back seasons and have jockeyed with one another for playoff position in seasons past. That figures to happen again in 2025, as Tampa Bay and Los Angeles are both expected to compete for division titles once again. The other element of this game? Baker Mayfield had a brief stint with the Rams in 2022, so it will be fun to monitor how Sean McVay schemes against his former quarterback. Week 13 Minnesota Vikings at Seattle Seahawks The Vikings replaced Sam Darnold with J.J. McCarthy this offseason. The two will face off in Week 13 in what could be an important game for Minnesota's chances of winning the NFC North. Darnold may relish an opportunity to diminish the Vikings' postseason chances, so that storyline should make this a fun game to watch. Week 14 Tennessee Titans at Cleveland Browns This game probably won't come with the same playoff intrigue as some of the others being played at this time of year. However, this could end up being a matchup between No. 1 overall pick Cam Ward and Shedeur Sanders, who endured one of the most surprising NFL draft slides in recent memory. Sanders was a fifth-round pick, so it's hardly guaranteed he will start this game. That said, the contest will still be of interest, as the Browns were reportedly interested in Ward during the draft process. He may have been the choice had he been on the board with the No. 2 overall pick, so Cleveland fans can get a glimpse of what the team's future might have been. Week 15 Baltimore Ravens at Cincinnati Bengals The matchup between Lamar Jackson and Joe Burrow is always exciting. It could be even more thrilling if the Ravens and Bengals are close together in the AFC North race at this late stage in the season. Week 16 Jacksonville Jaguars at Denver Broncos If you're looking for a good time to see Travis Hunter in action, this might be it. He played collegiately at Colorado, so this will be something of a homecoming for him. It will also be a great test of the two-way star's abilities, as he will be tasked with beating a stout Broncos defense on offense while covering a solid receiving corps led by Courtland Sutton and Marvin Mims Jr. Week 17 Philadelphia Eagles at Buffalo Bills The Chiefs edged the Bills in the AFC championship game last season, but Buffalo was close to winning the game and getting a chance to match up against the Eagles in Super Bowl 59. Perhaps their late-season meeting will end up being a preview of Super Bowl 60 instead. Week 18 Baltimore Ravens at Pittsburgh Steelers A classic, AFC North rivalry that could have playoff implications in Week 18? Sign us up, especially if Mike Tomlin needs to keep his consecutive streak of non-losing seasons alive.
